Skip to main content
OpenTrials
Completed

NCT Number: NCT01318122

Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

The purpose of this study was to evaluate the long-term safety and efficacy of alogliptin and Thiazolidine administered once daily (QD) for 40 consecutive weeks in participants who completed a phase 2/3 Thiazolidine add on study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

33 year–88 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

About this study

Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.

Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.

To evaluate the long-term safety and efficacy of alogliptin, participants in the present study were enrolled from a core phase 2/3 thiazolidine add on study (SYR-322/CCT-004; NCT01318070).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Had completed the core phase 2/3 thiazolidine add on study.
  • The subject was capable of understanding and complying with protocol requirements.
  • Signed a written, informed consent form prior to the initiation of any study procedure.

Exclusion criteria

  • With clinical manifestation of hepatic impairment (e.g., an AST or ALT value of 2.5 times or more of the upper reference limit at Week 8 of the core phase 2/3 thiazolidine add on study).
  • With clinical manifestation of renal impairment (e.g., a creatinine value of 2 mg/dL or more at Week 8 of the core phase 2/3 thiazolidine add on study).
  • With a history or symptoms of cardiac failure.

Treatment and study plan

Alogliptin and pioglitazone

Drug

Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.

Other names: SYR-322, Actos

Primary outcomes

  1. Number of Participants With Adverse Events.

    Time frame: 52 Weeks.

    Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.

Secondary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (Week 8).

    Time frame: Baseline and Week 8.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.

  2. Change From Baseline in Glycosylated Hemoglobin (Week 12).

    Time frame: Baseline and Week 12.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline.

  3. Change From Baseline in Glycosylated Hemoglobin (Week 16).

    Time frame: Baseline and Week 16.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline.

  4. Change From Baseline in Glycosylated Hemoglobin (Week 20).

    Time frame: Baseline and Week 20.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline.

  5. Change From Baseline in Glycosylated Hemoglobin (Week 24).

    Time frame: Baseline and Week 24.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline.

  6. Change From Baseline in Glycosylated Hemoglobin (Week 28).

    Time frame: Baseline and Week 28.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline.

  7. Change From Baseline in Glycosylated Hemoglobin (Week 32).

    Time frame: Baseline and Week 32.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline.

  8. Change From Baseline in Glycosylated Hemoglobin (Week 36).

    Time frame: Baseline and Week 36.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline.

  9. Change From Baseline in Glycosylated Hemoglobin (Week 40).

    Time frame: Baseline and Week 40.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline.

  10. Change From Baseline in Glycosylated Hemoglobin (Week 44).

    Time frame: Baseline and Week 44.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline.

  11. Change From Baseline in Glycosylated Hemoglobin (Week 48).

    Time frame: Baseline and Week 48.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline.

  12. Change From Baseline in Glycosylated Hemoglobin (Week 52).

    Time frame: Baseline and Week 52.

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline.

  13. Change From Baseline in Glycosylated Hemoglobin (Final Visit).

    Time frame: Baseline and Final Visit (up to Week 52).

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 or final visit and glycosylated hemoglobin collected at baseline.

  14. Change From Baseline in Fasting Blood Glucose (Week 8).

    Time frame: Baseline and Week 8.

    The change between the value of fasting blood glucose collected at week 8 and baseline.

  15. Change From Baseline in Fasting Blood Glucose (Week 12).

    Time frame: Baseline and Week 12.

    The change between the value of fasting blood glucose collected at week 12 and baseline.

  16. Change From Baseline in Fasting Blood Glucose (Week 16).

    Time frame: Baseline and Week 16.

    The change between the value of fasting blood glucose collected at week 6 and baseline.

  17. Change From Baseline in Fasting Blood Glucose (Week 20).

    Time frame: Baseline and Week 20.

    The change between the value of fasting blood glucose collected at week 20 and baseline.

  18. Change From Baseline in Fasting Blood Glucose (Week 24).

    Time frame: Baseline and Week 24.

    The change between the value of fasting blood glucose collected at week 24 and baseline.

  19. Change From Baseline in Fasting Blood Glucose (Week 28).

    Time frame: Baseline and Week 28.

    The change between the value of fasting blood glucose collected at week 28 and baseline.

  20. Change From Baseline in Fasting Blood Glucose (Week 32).

    Time frame: Baseline and Week 32.

    The change between the value of fasting blood glucose collected at week 32 and baseline.

  21. Change From Baseline in Fasting Blood Glucose (Week 36).

    Time frame: Baseline and Week 36.

    The change between the value of fasting blood glucose collected at week 36 and baseline.

  22. Change From Baseline in Fasting Blood Glucose (Week 40).

    Time frame: Baseline and Week 40.

    The change between the value of fasting blood glucose collected at week 40 and baseline.

  23. Change From Baseline in Fasting Blood Glucose (Week 44).

    Time frame: Baseline and Week 44.

    The change between the value of fasting blood glucose collected at week 44 and baseline.

  24. Change From Baseline in Fasting Blood Glucose (Week 48).

    Time frame: Baseline and Week 48.

    The change between the value of fasting blood glucose collected at week 48 and baseline.

  25. Change From Baseline in Fasting Blood Glucose (Week 52).

    Time frame: Baseline and Week 52.

    The change between the value of fasting blood glucose collected at week 52 and baseline.

  26. Change From Baseline in Fasting Blood Glucose (Final Visit).

    Time frame: Baseline and Final Visit (up to Week 52).

    The change between the value of fasting blood glucose collected at week 52 or final visit and baseline.

  27. Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).

    Time frame: Baseline and Week 12.

    The change between the value of blood glucose measured by the meal tolerance test collected at week 12 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.

  28. Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 24).

    Time frame: Baseline and Week 24.

    The change between the value of blood glucose measured by the meal tolerance test collected at week 24 and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.

  29. Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 52).

    Time frame: Baseline and Week 52.

    The change between the value of blood glucose measured by the meal tolerance test collected at week 52 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.

  30. Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Final Visit).

    Time frame: Baseline and Final Visit (up to Week 52).

    The change between the value of blood glucose measured by the meal tolerance test collected at week 52 or end of study and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Official study title

A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR-322 When Used in Combination With Thiazolidine in Subjects With Type 2 Diabetes in Japan

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Mar 18, 2011
Registry last updated
Feb 3, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.